HRP20080311T3 - Pyrazole derivatives, compositions containing such compounds and methods of use - Google Patents
Pyrazole derivatives, compositions containing such compounds and methods of useInfo
- Publication number
- HRP20080311T3 HRP20080311T3 HR20080311T HRP20080311T HRP20080311T3 HR P20080311 T3 HRP20080311 T3 HR P20080311T3 HR 20080311 T HR20080311 T HR 20080311T HR P20080311 T HRP20080311 T HR P20080311T HR P20080311 T3 HRP20080311 T3 HR P20080311T3
- Authority
- HR
- Croatia
- Prior art keywords
- groups
- alkyl
- optionally substituted
- halo
- group
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 150000003217 pyrazoles Chemical class 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000005843 halogen group Chemical group 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57711604P | 2004-06-04 | 2004-06-04 | |
| PCT/US2005/018828 WO2005121097A2 (en) | 2004-06-04 | 2005-05-31 | Pyrazole derivatives, compositions containing such compounds and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20080311T3 true HRP20080311T3 (en) | 2008-07-31 |
Family
ID=35335786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20080311T HRP20080311T3 (en) | 2004-06-04 | 2008-07-01 | Pyrazole derivatives, compositions containing such compounds and methods of use |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US7598285B2 (da) |
| EP (1) | EP1756064B1 (da) |
| JP (2) | JP4108739B2 (da) |
| CN (1) | CN1964947A (da) |
| AR (2) | AR049291A1 (da) |
| AT (1) | ATE395338T1 (da) |
| AU (2) | AU2005252183B2 (da) |
| BR (1) | BRPI0511703B8 (da) |
| CA (1) | CA2566945C (da) |
| CR (1) | CR8766A (da) |
| CY (1) | CY1108544T1 (da) |
| DE (1) | DE602005006806D1 (da) |
| DK (1) | DK1756064T3 (da) |
| EA (1) | EA012431B1 (da) |
| EC (1) | ECSP067062A (da) |
| ES (1) | ES2306165T3 (da) |
| GE (1) | GEP20094605B (da) |
| HR (1) | HRP20080311T3 (da) |
| IL (1) | IL179754A (da) |
| MA (1) | MA28673B1 (da) |
| MX (1) | MXPA06014084A (da) |
| MY (1) | MY143599A (da) |
| NI (1) | NI200600290A (da) |
| NO (1) | NO339149B1 (da) |
| NZ (1) | NZ551405A (da) |
| PE (1) | PE20060427A1 (da) |
| PL (1) | PL1756064T3 (da) |
| PT (1) | PT1756064E (da) |
| SI (1) | SI1756064T1 (da) |
| TN (1) | TNSN06397A1 (da) |
| TW (1) | TWI293952B (da) |
| UA (1) | UA85884C2 (da) |
| WO (1) | WO2005121097A2 (da) |
| ZA (1) | ZA200609489B (da) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004210127B2 (en) | 2003-01-27 | 2009-10-01 | Merck Sharp & Dohme Corp. | Substituted pyrazoles, compositions containing such compounds and methods of use |
| ES2306165T3 (es) | 2004-06-04 | 2008-11-01 | MERCK & CO., INC. | Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso. |
| US7625938B2 (en) | 2004-07-22 | 2009-12-01 | Merck & Co., Inc. | Substituted pyrazoles, compositions containing such compounds and methods of use |
| JP2009502923A (ja) | 2005-07-26 | 2009-01-29 | メルク エンド カムパニー インコーポレーテッド | 置換ピラゾールを合成するための方法 |
| AR056574A1 (es) * | 2005-10-19 | 2007-10-10 | Merck & Co Inc | Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso |
| EP2114891A1 (en) * | 2007-01-17 | 2009-11-11 | Laboratorios Del. Dr. Esteve, S.A. | Substituted pyrazoline compounds with acat inhibition activity |
| KR20170085615A (ko) | 2007-02-09 | 2017-07-24 | 메타베이시스 테라퓨틱스, 인크. | 글루카곤 수용체의 길항제 |
| WO2009005675A1 (en) * | 2007-06-28 | 2009-01-08 | Abbott Laboratories | Novel triazolopyridazines |
| US8232413B2 (en) * | 2007-09-12 | 2012-07-31 | Merck Sharp & Dohme Corp. | Process for the production of a crystalline glucagon receptor antagonist compound |
| CN102015641B (zh) | 2008-03-05 | 2014-01-01 | 武田药品工业株式会社 | 杂环化合物 |
| EP2251038B1 (en) | 2008-03-11 | 2017-05-10 | ASKA Pharmaceutical Co., Ltd. | Solid dispersion, pharmaceutical compositions containing the same, and processes for the production of both |
| US8623818B2 (en) | 2008-05-16 | 2014-01-07 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonists, compositions, and methods for their use |
| EP3153501B1 (en) | 2008-08-13 | 2018-11-28 | Metabasis Therapeutics, Inc. | Glucagon antagonists |
| RU2008135294A (ru) * | 2008-08-29 | 2010-03-10 | Дик Корпорейшн (Jp) | Нафталиновые производные |
| WO2010030722A1 (en) * | 2008-09-15 | 2010-03-18 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| US8361959B2 (en) * | 2008-10-03 | 2013-01-29 | Merck Sharp & Dohme Corp. | Spiro-imidazolone derivatives as glucagon receptor antagonists |
| US8324384B2 (en) | 2009-02-12 | 2012-12-04 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| WO2010098994A1 (en) | 2009-02-25 | 2010-09-02 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| US8470773B2 (en) | 2009-06-12 | 2013-06-25 | Merck Sharp & Dohme Corp. | Thiophenes as glucagon receptor antagonists, compositions, and methods for their use |
| EP2480077B1 (en) | 2009-09-22 | 2015-02-18 | Merck Sharp & Dohme Corp. | Pyrrolidines as glucagon receptor antagonists, compositions, and methods for their use |
| BR112013016033A2 (pt) | 2010-12-23 | 2018-06-05 | Pfizer | moduladores do receptor de glucagon |
| EA023517B1 (ru) | 2011-02-08 | 2016-06-30 | Пфайзер Инк. | Модуляторы глюкагонового рецептора |
| BR112014000288A2 (pt) | 2011-07-22 | 2017-01-10 | Pfizer | moduladores do receptor de glucagon de quinolinila |
| TW201427658A (zh) | 2012-12-10 | 2014-07-16 | Merck Sharp & Dohme | 藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法 |
| US9649294B2 (en) | 2013-11-04 | 2017-05-16 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| CN103933032B (zh) * | 2013-12-30 | 2019-08-23 | 北京赛林泰医药技术有限公司 | 作为抗癌药物的吡唑类衍生物的使用方法和用途 |
| US10076504B2 (en) | 2014-06-12 | 2018-09-18 | Ligand Pharmaceuticals, Inc. | Glucagon antagonists |
| CN109922831A (zh) | 2016-08-30 | 2019-06-21 | 瑞泽恩制药公司 | 通过干扰胰高血糖素受体的信号传导治疗重度胰岛素抵抗的方法 |
| TWI763705B (zh) * | 2016-09-06 | 2022-05-11 | 比利時商健生藥品公司 | 可作為升糖素受體拮抗劑之吲哚衍生物 |
| WO2018075792A1 (en) | 2016-10-20 | 2018-04-26 | Regeneron Pharmaceuticals, Inc. | Methods of lowering blood glucose levels |
| JP2020531532A (ja) | 2017-08-22 | 2020-11-05 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法 |
| CN111954560A (zh) | 2018-02-13 | 2020-11-17 | 配体药物公司 | 胰高血糖素受体拮抗剂 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9303993D0 (en) | 1993-02-26 | 1993-04-14 | Fujisawa Pharmaceutical Co | New heterocyclic derivatives |
| EP0859771A4 (en) | 1995-10-31 | 2000-03-15 | Merck & Co Inc | SUBSTITUTED PYRIDYL PYRROLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHOD OF USE |
| AR008789A1 (es) | 1996-07-31 | 2000-02-23 | Bayer Corp | Piridinas y bifenilos substituidos |
| US5776954A (en) | 1996-10-30 | 1998-07-07 | Merck & Co., Inc. | Substituted pyridyl pyrroles, compositions containing such compounds and methods of use |
| JP2000514088A (ja) | 1996-11-20 | 2000-10-24 | メルク エンド カンパニー インコーポレーテッド | グルカゴンアンタゴニストとしてのトリアリール置換イミダゾール |
| CA2271963A1 (en) | 1996-11-20 | 1998-05-28 | Linda L. Chang | Triaryl substituted imidazoles, compositions containing such compounds and methods of use |
| EP0959885A4 (en) | 1996-11-20 | 2002-07-17 | Merck & Co Inc | TRIARYL SUBSTITUTED IMIDAZOLES AND METHODS OF USE |
| EP0945438B1 (en) | 1996-12-12 | 2003-03-05 | Banyu Pharmaceutical Co., Ltd. | Pyrazole derivatives |
| EP0979077A1 (en) | 1997-04-18 | 2000-02-16 | G.D. Searle & Co. | Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders |
| US6613942B1 (en) | 1997-07-01 | 2003-09-02 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
| US6420427B1 (en) | 1997-10-09 | 2002-07-16 | Ono Pharmaceutical Co., Ltd. | Aminobutyric acid derivatives |
| KR20010033241A (ko) | 1997-12-19 | 2001-04-25 | 스티븐 엠. 오드레 | 치환된 피리딘 및 피리다진 화합물과 그것의 제약학적 용도 |
| BR9913833A (pt) | 1998-09-17 | 2001-05-29 | Bristol Myers Squibb Co | Método para tratar diabetes, empregando em inibidor de ap2 e combinação |
| US6503949B1 (en) | 1999-05-17 | 2003-01-07 | Noro Nordisk A/S | Glucagon antagonists/inverse agonists |
| PL364750A1 (en) | 1999-08-10 | 2004-12-13 | Nihon Bayer Agrochem K.K. | Herbicidal tetrazolinone derivatives |
| HUP0203165A3 (en) * | 1999-11-10 | 2004-03-29 | Takeda Pharmaceutical | 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity |
| US6562807B2 (en) | 2000-06-23 | 2003-05-13 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
| AU2001277056B2 (en) * | 2000-07-25 | 2005-09-29 | Merck & Co., Inc. | N-substituted indoles useful in the treatment of diabetes |
| WO2002040444A1 (en) | 2000-11-17 | 2002-05-23 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
| US20030203946A1 (en) | 2000-11-17 | 2003-10-30 | Carsten Behrens | Glucagon antagonists/inverse agonists |
| ITMI20010733A1 (it) | 2001-04-05 | 2002-10-05 | Recordati Chem Pharm | Uso di inibitori dell'isoenzina cox-2 per il trattamento dell'incontinenza urinaria |
| US6881746B2 (en) | 2001-12-03 | 2005-04-19 | Novo Nordick A/S | Glucagon antagonists/inverse agonists |
| US6762318B2 (en) | 2001-12-03 | 2004-07-13 | Novo Nordisk A/S | Glucagon antagonists |
| WO2003051357A1 (en) | 2001-12-19 | 2003-06-26 | Novo Nordisk A/S | Glucagon receptor antagonists/inverse agonists |
| WO2003053938A1 (en) | 2001-12-20 | 2003-07-03 | Novo Nordisk A/S | Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten |
| CA2473591C (en) | 2002-02-01 | 2011-11-01 | Dainippon Pharmaceutical Co., Ltd. | 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same |
| ATE505223T1 (de) | 2002-07-19 | 2011-04-15 | Baxter Int | System für die peritonealdialyse |
| EP1400243A1 (en) | 2002-09-19 | 2004-03-24 | Tanabe Seiyaku Co., Ltd. | Calcium-activated K channel activator |
| JP2006509015A (ja) * | 2002-12-04 | 2006-03-16 | メルク エンド カムパニー インコーポレーテッド | スピロ環尿素、そのような化合物を含有する組成物、及び使用方法 |
| AU2004210127B2 (en) * | 2003-01-27 | 2009-10-01 | Merck Sharp & Dohme Corp. | Substituted pyrazoles, compositions containing such compounds and methods of use |
| US20040248937A1 (en) * | 2003-04-14 | 2004-12-09 | The Institute For Pharmaceutical Discovery Llc | Substituted phenylalkanoic acids for the treatment of diabetes |
| AU2004238240A1 (en) * | 2003-05-09 | 2004-11-25 | Merck & Co., Inc. | Benzimidazoles, compositions containing such compounds and methods of use |
| ES2306165T3 (es) * | 2004-06-04 | 2008-11-01 | MERCK & CO., INC. | Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso. |
| US7625938B2 (en) * | 2004-07-22 | 2009-12-01 | Merck & Co., Inc. | Substituted pyrazoles, compositions containing such compounds and methods of use |
| AR056574A1 (es) * | 2005-10-19 | 2007-10-10 | Merck & Co Inc | Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso |
-
2005
- 2005-05-31 ES ES05754758T patent/ES2306165T3/es active Active
- 2005-05-31 DK DK05754758T patent/DK1756064T3/da active
- 2005-05-31 CA CA2566945A patent/CA2566945C/en not_active Expired - Fee Related
- 2005-05-31 EA EA200602196A patent/EA012431B1/ru not_active IP Right Cessation
- 2005-05-31 SI SI200530296T patent/SI1756064T1/sl unknown
- 2005-05-31 BR BRPI0511703A patent/BRPI0511703B8/pt not_active IP Right Cessation
- 2005-05-31 WO PCT/US2005/018828 patent/WO2005121097A2/en active IP Right Grant
- 2005-05-31 JP JP2007515416A patent/JP4108739B2/ja not_active Expired - Fee Related
- 2005-05-31 DE DE602005006806T patent/DE602005006806D1/de active Active
- 2005-05-31 AU AU2005252183A patent/AU2005252183B2/en not_active Ceased
- 2005-05-31 NZ NZ551405A patent/NZ551405A/en not_active IP Right Cessation
- 2005-05-31 MY MYPI20052470A patent/MY143599A/en unknown
- 2005-05-31 GE GEAP20059788A patent/GEP20094605B/en unknown
- 2005-05-31 AT AT05754758T patent/ATE395338T1/de active
- 2005-05-31 PT PT05754758T patent/PT1756064E/pt unknown
- 2005-05-31 UA UAA200700111A patent/UA85884C2/uk unknown
- 2005-05-31 MX MXPA06014084A patent/MXPA06014084A/es active IP Right Grant
- 2005-05-31 EP EP05754758A patent/EP1756064B1/en active Active
- 2005-05-31 PL PL05754758T patent/PL1756064T3/pl unknown
- 2005-05-31 CN CNA2005800182634A patent/CN1964947A/zh active Pending
- 2005-06-02 AR ARP050102266A patent/AR049291A1/es active IP Right Grant
- 2005-06-02 PE PE2005000624A patent/PE20060427A1/es not_active Application Discontinuation
- 2005-06-03 TW TW094118496A patent/TWI293952B/zh not_active IP Right Cessation
- 2005-06-03 US US11/144,332 patent/US7598285B2/en active Active
-
2006
- 2006-11-15 ZA ZA200609489A patent/ZA200609489B/en unknown
- 2006-11-23 CR CR8766A patent/CR8766A/es unknown
- 2006-11-30 NI NI200600290A patent/NI200600290A/es unknown
- 2006-11-30 IL IL179754A patent/IL179754A/en active IP Right Grant
- 2006-12-01 TN TNP2006000397A patent/TNSN06397A1/en unknown
- 2006-12-04 EC EC2006007062A patent/ECSP067062A/es unknown
- 2006-12-20 MA MA29545A patent/MA28673B1/fr unknown
-
2007
- 2007-01-04 NO NO20070073A patent/NO339149B1/no not_active IP Right Cessation
-
2008
- 2008-02-05 JP JP2008025035A patent/JP4733153B2/ja not_active Expired - Fee Related
- 2008-07-01 HR HR20080311T patent/HRP20080311T3/xx unknown
- 2008-07-21 CY CY20081100762T patent/CY1108544T1/el unknown
- 2008-09-30 AU AU2008229701A patent/AU2008229701C1/en not_active Ceased
-
2009
- 2009-03-17 US US12/405,600 patent/US7799818B2/en active Active
-
2012
- 2012-11-20 AR ARP120104354A patent/AR088919A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20080311T3 (en) | Pyrazole derivatives, compositions containing such compounds and methods of use | |
| RS52326B (en) | Phenyl-piperazine Derivatives As Serotonin Resorption Inhibitors | |
| RS52702B (en) | CARBASOL UNITS AND THERAPEUTIC USE OF THE COMPOUNDS | |
| RS52313B (en) | MYTHOSIS PROGRESS INHIBITION UNITS | |
| HRP20000854B1 (en) | Therapeutic biaryl derivatives | |
| RS52216B (en) | UNITS AND METHODS FOR FXR MODULATION | |
| RS54723B1 (en) | CONDENSED IMIDASOL DERIVATIVES USEFUL AS IDO INHIBITORS | |
| TW200745034A (en) | New compounds | |
| RS51280B (sr) | Novi derivati hidantoina za tretman obstruktivnih bolesti dišnih puteva | |
| RS54776B1 (sr) | Fosforoamidatni derivati 5-fluoro-2'-dezoksiuridina za upotrebu u tretmanu kancera | |
| HRP20110498T1 (hr) | Azetidini kao inhibitori mek za liječenje proliferativnih bolesti | |
| RS50919B (sr) | Derivati merkaptoacetilamida, postupak za njihovo pripremanje i njihova upotreba | |
| PH12014501033A1 (en) | Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | |
| RS51549B (en) | HETEROARIL UNITS USEFUL AS INVESTIGATIVE ENZYME E1 INHIBITORS | |
| RS54798B1 (sr) | Pozitivni alosterni modulatori m1 receptora na bazi hinolin amida | |
| RS54260B1 (en) | AMINODIHYDROTIAZINE DERIVATIVES AS BACE INHIBITORS FOR ALZHEIMER DISEASE TREATMENT | |
| HRP20000406B1 (en) | Arylpiperazines having activity at the serotonin 1a receptor | |
| ME01421B (me) | 5-supstituisani derivati kinazolinona kao protivtumorska sredstva | |
| HRP20070529T3 (en) | Imidazole derivatives as glutmate receptor antagonists | |
| RS53153B (en) | ANTAGONISTS OF HYSTAMINE -3 RECEPTORS | |
| RS50519B (sr) | Supstituisani derivati 8'-piri(mi)dinil-dihidrospiro- /cikloalkilamin/-pirimido/1,2-a/pirimidin-6-ona | |
| RS51674B (en) | PIPERIDIN-4-IL-PIRIDAZIN-3-ILAMINE DERIVATIVES AS A FAST DISSOCATING DOPAMIN 2 RECEIVER ANTAGONISTS | |
| RS52661B (en) | THERAPEUTIC MEANS | |
| RS52261B (en) | AMIDOPHENOX INDASOLS AS A USEFUL C-MET INHIBITOR | |
| RS53038B (en) | OXADIAZOLA DERIVATIVE Activate Sphingosine-1-Phosphate (SIP) |